{"title":"羟嗪与三氯福在儿童脑电图记录中的镇静作用:一项非劣效性随机对照试验","authors":"Narmadham K. Bharathi MD, DM , Sangeetha Yoganathan MD, DNB, DM , Maya Thomas DCH, MD, DM , Annadurai Subramanian MPharm, PhD (Pharmacy) , Antonisamy Belavendra PhD , Winsley Rose MD, MSc (Epi) , Yezhilarasi Ganesan BSc (Chem)","doi":"10.1016/j.pediatrneurol.2025.05.028","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Triclofos is commonly used for sedation in children for electroencephalography (EEG) recording. A noninferiority randomized controlled trial was conducted to assess the efficacy, safety, and acceptability of hydroxyzine as an alternate drug for sedation.</div></div><div><h3>Methods</h3><div>Children aged six months to five years who did not sleep naturally for EEG recording were randomly assigned to receive either hydroxyzine or triclofos in 1:1 ratio. Our primary outcome was successful EEG completion as defined by achieving at least 40 minutes of sleep record in a one-hour EEG recording. Our secondary outcomes were Ramsay sedation score, time taken for sedation, need for second dose of sedative agent, yield of abnormal EEG records, incidence of adverse events, technologist and caregiver satisfaction score (based on a Likert scale), neurologist assessment of motion artifacts based on a visual analog scale, and effect of the drug on the amplitude and frequency of the background rhythm. The parents were interviewed telephonically regarding any adverse effects within the next 24 hours.</div></div><div><h3>Results</h3><div>Successful EEG completion was achieved in 82.6% in the hydroxyzine arm and in 90.2% in the triclofos arm with a mean difference of −7.66 (95% confidence interval: −16.5 to 1.2, <em>P</em> = 0.092). Secondary outcomes such as time taken to sleep, need for second dose of sedation, yield of abnormal EEG records, adverse effect profile, neurologist grading of motion artifacts, and effect on background were comparable between both groups.</div></div><div><h3>Conclusion</h3><div>Hydroxyzine may be a safe, acceptable, and efficacious alternative sedative agent for EEG recording in children.</div></div>","PeriodicalId":19956,"journal":{"name":"Pediatric neurology","volume":"170 ","pages":"Pages 4-10"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hydroxyzine Versus Triclofos for Sedation for Electroencephalography Recording in Children: A Noninferiority Randomized Controlled Trial\",\"authors\":\"Narmadham K. Bharathi MD, DM , Sangeetha Yoganathan MD, DNB, DM , Maya Thomas DCH, MD, DM , Annadurai Subramanian MPharm, PhD (Pharmacy) , Antonisamy Belavendra PhD , Winsley Rose MD, MSc (Epi) , Yezhilarasi Ganesan BSc (Chem)\",\"doi\":\"10.1016/j.pediatrneurol.2025.05.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Triclofos is commonly used for sedation in children for electroencephalography (EEG) recording. A noninferiority randomized controlled trial was conducted to assess the efficacy, safety, and acceptability of hydroxyzine as an alternate drug for sedation.</div></div><div><h3>Methods</h3><div>Children aged six months to five years who did not sleep naturally for EEG recording were randomly assigned to receive either hydroxyzine or triclofos in 1:1 ratio. Our primary outcome was successful EEG completion as defined by achieving at least 40 minutes of sleep record in a one-hour EEG recording. Our secondary outcomes were Ramsay sedation score, time taken for sedation, need for second dose of sedative agent, yield of abnormal EEG records, incidence of adverse events, technologist and caregiver satisfaction score (based on a Likert scale), neurologist assessment of motion artifacts based on a visual analog scale, and effect of the drug on the amplitude and frequency of the background rhythm. The parents were interviewed telephonically regarding any adverse effects within the next 24 hours.</div></div><div><h3>Results</h3><div>Successful EEG completion was achieved in 82.6% in the hydroxyzine arm and in 90.2% in the triclofos arm with a mean difference of −7.66 (95% confidence interval: −16.5 to 1.2, <em>P</em> = 0.092). Secondary outcomes such as time taken to sleep, need for second dose of sedation, yield of abnormal EEG records, adverse effect profile, neurologist grading of motion artifacts, and effect on background were comparable between both groups.</div></div><div><h3>Conclusion</h3><div>Hydroxyzine may be a safe, acceptable, and efficacious alternative sedative agent for EEG recording in children.</div></div>\",\"PeriodicalId\":19956,\"journal\":{\"name\":\"Pediatric neurology\",\"volume\":\"170 \",\"pages\":\"Pages 4-10\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0887899425001523\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887899425001523","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Hydroxyzine Versus Triclofos for Sedation for Electroencephalography Recording in Children: A Noninferiority Randomized Controlled Trial
Background
Triclofos is commonly used for sedation in children for electroencephalography (EEG) recording. A noninferiority randomized controlled trial was conducted to assess the efficacy, safety, and acceptability of hydroxyzine as an alternate drug for sedation.
Methods
Children aged six months to five years who did not sleep naturally for EEG recording were randomly assigned to receive either hydroxyzine or triclofos in 1:1 ratio. Our primary outcome was successful EEG completion as defined by achieving at least 40 minutes of sleep record in a one-hour EEG recording. Our secondary outcomes were Ramsay sedation score, time taken for sedation, need for second dose of sedative agent, yield of abnormal EEG records, incidence of adverse events, technologist and caregiver satisfaction score (based on a Likert scale), neurologist assessment of motion artifacts based on a visual analog scale, and effect of the drug on the amplitude and frequency of the background rhythm. The parents were interviewed telephonically regarding any adverse effects within the next 24 hours.
Results
Successful EEG completion was achieved in 82.6% in the hydroxyzine arm and in 90.2% in the triclofos arm with a mean difference of −7.66 (95% confidence interval: −16.5 to 1.2, P = 0.092). Secondary outcomes such as time taken to sleep, need for second dose of sedation, yield of abnormal EEG records, adverse effect profile, neurologist grading of motion artifacts, and effect on background were comparable between both groups.
Conclusion
Hydroxyzine may be a safe, acceptable, and efficacious alternative sedative agent for EEG recording in children.
期刊介绍:
Pediatric Neurology publishes timely peer-reviewed clinical and research articles covering all aspects of the developing nervous system.
Pediatric Neurology features up-to-the-minute publication of the latest advances in the diagnosis, management, and treatment of pediatric neurologic disorders. The journal''s editor, E. Steve Roach, in conjunction with the team of Associate Editors, heads an internationally recognized editorial board, ensuring the most authoritative and extensive coverage of the field. Among the topics covered are: epilepsy, mitochondrial diseases, congenital malformations, chromosomopathies, peripheral neuropathies, perinatal and childhood stroke, cerebral palsy, as well as other diseases affecting the developing nervous system.